Dacepton® (apomorphine hydrochloride) is indicated for the treatment of motor fluctuations ("on-off" phenomena) in patients with Parkinson’s disease which are not sufficiently controlled by oral anti-Parkinson medication.1
Dacepton® may be administered by either intermittent subcutaneous injection at the beginning of “off“ phases, or by continuous subcutaneous infusion.
- Dacepton® 10 mg/ml is for subcutaneous use by intermittent bolus injection.1
- Dacepton® 5 mg/ml solution for infusion is a pre-diluted vial intended for use without dilution for subcutaneous use and to be administered as a continuous subcutaneous infusion by minipump (D-mine® Pump) and/or syringe-driver. It is not intended to be used for intermittent injection.1
1 SmPC Dacepton® 5mg/ml Vial solution for infusion (https://www.medicines.org.uk/emc/product/9632/smpc#gref), SmPC Dacepton® 10mg/ml Cartridge solution for injection (https://www.medicines.org.uk/emc/product/9650/smpc#gref).